According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.

A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.

Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.